Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.95 USD | -0.38% | -6.82% | -23.08% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.08% | 230M | |
+10.94% | 227B | |
+15.24% | 198B | |
+18.04% | 142B | |
+31.29% | 111B | |
+1.56% | 64.16B | |
+18.26% | 54.1B | |
+5.12% | 51.41B | |
+10.77% | 45.32B | |
+5.54% | 37.32B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Transcript : NeuroPace, Inc., Q3 2023 Earnings Call, Nov 06, 2023